Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

SYSTEMIC LUPUS ERYTHEMATOSUS

Ikaros, Aiolos and other moving targets to treat SLE

Nature Reviews Rheumatology volume 18, pages 499–500 (2022)Cite this article

Subjects

Although the multitude of pathways involved in the pathogenesis of systemic lupus erythematosus (SLE) seem to be interconnected, each predominates in only a fraction of patients. This complexity means that many agents tested in SLE clinical trials — now including iberdomide — produce only a small clinical benefit.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: E3 ubiquitin ligases in the pathogenesis of SLE.

References

  1. Tsokos, G. C. Autoimmunity and organ damage in systemic lupus erythematosus. Nat. Immunol. 21, 605–614 (2020).

    Article  CAS  Google Scholar 

  2. Merrill, J. T. et al. Phase 2 trial of iberdomide in systemic lupus erythematosus. N. Engl. J. Med. 386, 1034–1045 (2022).

    Article  CAS  Google Scholar 

  3. Georgopoulos, K. The making of a lymphocyte: the choice among disparate cell fates and the IKAROS enigma. Genes Dev. 31, 439–450 (2017).

    Article  CAS  Google Scholar 

  4. Vyse, T. J. & Cunninghame Graham, D. S. Trans-ancestral fine-mapping and epigenetic annotation as tools to delineate functionally relevant risk alleles at IKZF1 and IKZF3 in systemic lupus erythematosus. Int. J. Mol. Sci. 21, 8383 (2020).

    Article  CAS  Google Scholar 

  5. Nakayama, Y. et al. Aiolos overexpression in systemic lupus erythematosus B cell subtypes and BAFF-induced memory B cell differentiation are reduced by CC-220 modulation of cereblon activity. J. Immunol. 199, 2388–2407 (2017).

    Article  CAS  Google Scholar 

  6. Whiting, C. C., Su, L. L., Lin, J. T. & Garrison Fathman, C. GRAIL: a unique mediator of CD4 T-lymphocyte unresponsiveness. FEBS J. 278, 47–58 (2011).

    Article  CAS  Google Scholar 

  7. Tang, J. et al. Sequential ubiquitination of NLRP3 by RNF125 and Cbl-b limits inflammasome activation and endotoxemia. J. Exp. Med. 217, e20182091 (2020).

    Article  Google Scholar 

  8. Moulton, V. R. & Tsokos, G. C. T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity. J. Clin. Invest. 125, 2220–2227 (2015).

    Article  Google Scholar 

  9. Guo, Y., Zhao, M. & Lu, Q. Transcription factor RFX1 is ubiquitinated by E3 ligase STUB1 in systemic lupus erythematosus. Clin. Immunol. 169, 1–7 (2016).

    Article  CAS  Google Scholar 

  10. Ito, T. & Handa, H. Molecular mechanisms of thalidomide and its derivatives. Proc. Jpn. Acad. Ser. B 96, 189–203 (2020).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology and Clinical Immunology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    Afroditi Boulougoura & George C. Tsokos

Authors
  1. Afroditi Boulougoura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. George C. Tsokos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George C. Tsokos.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Boulougoura, A., Tsokos, G.C. Ikaros, Aiolos and other moving targets to treat SLE. Nat Rev Rheumatol 18, 499–500 (2022). https://doi.org/10.1038/s41584-022-00815-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41584-022-00815-2

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing